Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy - PubMed (original) (raw)
J Blankson, J D Siliciano, J B Margolick, K Chadwick, T Pierson, K Smith, J Lisziewicz, F Lori, C Flexner, T C Quinn, R E Chaisson, E Rosenberg, B Walker, S Gange, J Gallant, R F Siliciano
Affiliations
- PMID: 10229227
- DOI: 10.1038/8394
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
D Finzi et al. Nat Med. 1999 May.
Abstract
Combination therapy for HIV-1 infection can reduce plasma virus to undetectable levels, indicating that prolonged treatment might eradicate the infection. However, HIV-1 can persist in a latent form in resting CD4+ T cells. We measured the decay rate of this latent reservoir in 34 treated adults whose plasma virus levels were undetectable. The mean half-life of the latent reservoir was very long (43.9 months). If the latent reservoir consists of only 1 x 10(5) cells, eradication could take as long as 60 years. Thus, latent infection of resting CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective anti-retroviral therapy.
Comment in
- HIV-1 and HAART: a time to cure, a time to kill.
Saag MS, Kilby JM. Saag MS, et al. Nat Med. 1999 Jun;5(6):609-11. doi: 10.1038/9452. Nat Med. 1999. PMID: 10371490 No abstract available. - The QUEST trial, a paradigm of HIV collaborative research.
Goh LE, McDade H, Kinloch S, Perrin L, Cooper D, Phillips A, Hoen B, Autran B, Sonnerborg A, Tsoukas C. Goh LE, et al. Nat Med. 2000 Nov;6(11):1194. doi: 10.1038/81251. Nat Med. 2000. PMID: 11062508 No abstract available.
Similar articles
- The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.
Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, Macken CA, Perelson AS, Markowitz M, Ho DD. Ramratnam B, et al. Nat Med. 2000 Jan;6(1):82-5. doi: 10.1038/71577. Nat Med. 2000. PMID: 10613829 - Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M, Ho DD. Zhang L, et al. N Engl J Med. 1999 May 27;340(21):1605-13. doi: 10.1056/NEJM199905273402101. N Engl J Med. 1999. PMID: 10341272 Clinical Trial. - Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T, McArthur J, Siliciano RF. Pierson T, et al. Annu Rev Immunol. 2000;18:665-708. doi: 10.1146/annurev.immunol.18.1.665. Annu Rev Immunol. 2000. PMID: 10837072 Review. - Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.
Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF. Chun TW, et al. Nature. 1997 May 8;387(6629):183-8. doi: 10.1038/387183a0. Nature. 1997. PMID: 9144289 - Inducible HIV RNA transcription assays to measure HIV persistence: pros and cons of a compromise.
Plantin J, Massanella M, Chomont N. Plantin J, et al. Retrovirology. 2018 Jan 17;15(1):9. doi: 10.1186/s12977-017-0385-y. Retrovirology. 2018. PMID: 29343255 Free PMC article. Review.
Cited by
- In vivo effects of antiviral protein kinase C modulators on zebrafish development and survival.
Davis RV, McKernan LN, Rhodes J, Kulkosky J. Davis RV, et al. ISRN Toxicol. 2011 Dec 20;2011:248280. doi: 10.5402/2011/248280. Print 2011. ISRN Toxicol. 2011. PMID: 23724279 Free PMC article. - Alpaca-derived nanobody targeting the hydrophobic pocket of the HIV-1 gp41 NHR broadly neutralizes HIV-1 by blocking six-helix bundle formation.
Sun L, Chen B, Liu X, Zhu Y, Zhang G, Liang X, Xing L, Xu W, Jiang S, Wang X. Sun L, et al. Curr Res Microb Sci. 2024 Jul 22;7:100263. doi: 10.1016/j.crmicr.2024.100263. eCollection 2024. Curr Res Microb Sci. 2024. PMID: 39176008 Free PMC article. - Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers.
Policicchio BB, Xu C, Brocca-Cofano E, Raehtz KD, He T, Ma D, Li H, Sivanandham R, Haret-Richter GS, Dunsmore T, Trichel A, Mellors JW, Hahn BH, Shaw GM, Ribeiro RM, Pandrea I, Apetrei C. Policicchio BB, et al. PLoS Pathog. 2016 Sep 15;12(9):e1005879. doi: 10.1371/journal.ppat.1005879. eCollection 2016 Sep. PLoS Pathog. 2016. PMID: 27632364 Free PMC article. - Targeted Chromatinization and Repression of HIV-1 Provirus Transcription with Repurposed CRISPR/Cas9.
Olson A, Basukala B, Lee S, Gagne M, Wong WW, Henderson AJ. Olson A, et al. Viruses. 2020 Oct 12;12(10):1154. doi: 10.3390/v12101154. Viruses. 2020. PMID: 33053801 Free PMC article. - Sustained antiviral response against in vitro HIV-1 infection in peripheral blood mononuclear cells from people with chronic myeloid leukemia treated with ponatinib.
Manzanares M, Ramos-Martín F, Rodríguez-Mora S, Casado-Fernández G, Sánchez-Menéndez C, Simón-Rueda A, Mateos E, Cervero M, Spivak AM, Planelles V, Torres M, García-Gutiérrez V, Coiras M. Manzanares M, et al. Front Pharmacol. 2024 Sep 23;15:1426974. doi: 10.3389/fphar.2024.1426974. eCollection 2024. Front Pharmacol. 2024. PMID: 39380908 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials